Go to content Go to the menu Go to the search

Quick access, personalized services

Search

Advanced search

Contact

Claire de Thoisy-Méchin
Press attaché
Tel. (33) 1 44 27 23 34

E-mail : claire.de_thoisy-mechin@upmc.fr

First Injection of Cultured Red Blood Cells in Human Donor

Researchers Successfully Perform First Injection of Cultured Red Blood Cells in Human Donor

For the first time, researchers have successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor, according to study results published today in Blood, the Journal of the American Society of Hematology (ASH). As the global need for blood continues to increase while the number of blood donors is decreasing, these study results provide hope that one day patients in need of a blood transfusion might become their own donors.

 

Using HSCs (stem cells that form all blood cell types) from one human donor, a Paris-based research team successfully generated billions of cRBCs in a petri dish with the aid of specific growth factors that regulate the proliferation and maturation of HSCs into red blood cells. Seeking to prove that the cRBCs were capable of reaching full maturation in the body, the researchers then injected the cells into four mouse models and confirmed that the cells were able to progress through the full maturation process. Using a volunteer donor, the researchers then repeated the process of creating another set of cRBCs and injected the cells back into the donor’s own body to assess their survival in a human. After five days, the survival rate of the cRBCs in the donor’s bloodstream was between 94 and 100 percent and, after 26 days, the rate was between 41 and 63 percent, comparable to the average 28-day half-life of normal native red blood cells. These results demonstrate that the lifespan and survival rate of cultured cells are similar to conventional red blood cells, further supporting their validity as a possible source of transfusion.

“Although previous research has shown that HSCs can be developed into fully matured red blood cells, this is the first study that has proven that they are capable of survival in the human body, a major breakthrough for the transplant community,” said Luc Douay, MD, PhD, senior study author and Professor of Hematology at Université Pierre et Marie Curie in Paris, France. “There is a dire need for an alternative source of transfusable blood products, especially with the risk of infection from emergent new viruses that comes with traditional transfusion. Producing red blood cells in culture is promising since other efforts to create alternative sources have not yet been as successful as once hoped.”

 

These results are especially timely, as blood donation organizations such as the American Red Cross have recently declared a critical nationwide blood shortage. Globally, the World Health Organization (WHO) recently reported donation rates of less than 1 percent of the population in more than 70 countries. Many of these countries are considered developing or transitional and have substantial transfusion needs due to high prevalence of maternal morbidity, childhood malnutrition, trauma casualties, and infectious disease. [1]

“The results from our study establish the feasibility of the concept of transfusing cRBCs and show promise that an unlimited blood reserve is within reach,” said Professor Douay. “Although the full-scale production of these cells will require additional technological advances in cell engineering, we believe cRBCs could prove to be a valid alternative to classic transfusion products that will not only provide an adequate supply of blood, but reduce the risk of life-threatening complications and infections that can accompany traditional transfusion.”

 

Reporters who wish to receive a copy of the study or arrange an interview with the authors may contact Claire Gwayi-Chore at 202-776-0544 or cgwayi-chore@hematology.org.

 

The American Society of Hematology (www.hematology.org) is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.

[1] World Health Organization. http://www.who.int/mediacentre/factsheets/fs279/en/index.htmlNouvelle fenêtre. Accessed August 19, 2011.

 

BloodNouvelle fenêtre, first published online September 1, 2011

American Society of HematologyNouvelle fenêtre                                     

Sources

Proof of principle for transfusion of in vitro generated red blood cells              

Marie-Catherine Giarratana1,2*, Hélène Rouard3, 4*, Agnès Dumont5, Laurent Kiger6, Innocent Safeukui7, Pierre-Yves Le Pennec8, Sabine François1,2,9, Germain Trugnan10, Thierry Peyrard8, Tiffany Marie1,2,3, Séverine Jolly1,2,3, Nicolas Hebert1,2,3, Christelle Mazurier1,2,3, Nathalie Mario11, Laurence Harmand1,2,3, Hélène Lapillonne1,2,12, Jean-Yves Devaux5 and Luc Douay1, 2, 3, 13.

* These two authors contributed equally to this work.

1. UPMC Univ Paris 06, UMR_S938 CDR Saint-Antoine, Prolifération et Différentiation des Cellules Souches, F-75012, Paris                            

2. INSERM, UMR_S938, Prolifération et Différentiation des Cellules Souches Paris                                                                                               

3. EFS Ile de France, Unité d’Ingénierie et de Thérapie Cellulaire, Créteil, F-94017                                                                                                          

4. UPEC, Université Paris Est Créteil, F-94010                                               

5. AP-HP Hôpital St Antoine, Service de Médecine Nucléaire, F-75012 Paris             

6. INSERM U473, Hôpital du Kremlin-Bicêtre, F-94276, Kremlin-Bicêtre                 

7. CNRS URA 2581, Institut Pasteur, Molecular Immunology of Parasites Unit, F-75015 Paris                                                                                                  

8. CNRGS, INTS, F-75011 Paris                                                                         

9. IRSN, BP 17, F-92260 Fontenay-aux-Roses                                                    

10. UPMC Univ Paris 06; ERL INSERM U1057/UMR7203; FMPMC, F-75012 Paris     

11. AP-HP, Hôpital Saint-Antoine, Service de Biochimie A, F-75012 Paris, France.  

12. AP-HP, Hôpital Trousseau, Service d’Hématologie Biologique, F-75012 Paris     

13. AP-HP, Hôpital St Antoine, Service d’Hématologie et Immunologie Biologiques, F-75012 Paris, France.



08/09/11